LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $97.60 Average Price Target from Analysts

Key Points

• Analysts have assigned LeMaitre Vascular, Inc. (NASDAQ:LMAT) an average rating of "Hold", with three hold ratings and two buy ratings, and a 12-month price target of $97.60.
• The company reported $0.60 EPS for the quarter, surpassing estimates, and experienced a 15% year-over-year revenue growth, reaching $63.15 million.
• LeMaitre Vascular recently announced a quarterly dividend of $0.20 per share, representing an annualized dividend yield of 0.8%, with a payout ratio of 38.83%.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have earned a consensus recommendation of "Hold" from the five brokerages that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $97.60.

A number of research analysts have recently issued reports on LMAT shares. Cantor Fitzgerald boosted their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a report on Wednesday, August 6th.

Insiders Place Their Bets

In related news, Director John A. Roush sold 6,561 shares of the company's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the transaction, the director owned 2,916 shares of the company's stock, valued at $269,875.80. This represents a 69.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 100,000 shares of the company's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the transaction, the chief executive officer directly owned 1,727,003 shares in the company, valued at $161,492,050.53. This represents a 5.47% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 120,815 shares of company stock worth $11,280,206. Insiders own 9.50% of the company's stock.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently bought and sold shares of LMAT. Parkside Financial Bank & Trust boosted its position in LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 287 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the first quarter valued at $26,000. NBC Securities Inc. purchased a new stake in shares of LeMaitre Vascular in the first quarter valued at $36,000. Geneos Wealth Management Inc. lifted its position in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after acquiring an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the second quarter valued at $47,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

LMAT traded up $0.63 during trading on Wednesday, hitting $92.92. 19,231 shares of the stock were exchanged, compared to its average volume of 186,881. The firm has a market capitalization of $2.10 billion, a P/E ratio of 45.11, a PEG ratio of 2.37 and a beta of 0.79. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $109.58. The stock has a fifty day moving average price of $89.69 and a two-hundred day moving average price of $85.84. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, topping the consensus estimate of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm's revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, sell-side analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is currently 38.83%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.